Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11073212 | 0.97 | ALDH1A1 (0.41) | ALDH1A1TDP1L3MBTL1KDM4ECYP1A2 | |
| Cyclopropane SCHEMBL27460936 | 0.77 | ALDH1A1 (0.57) | ALDH1A1TDP1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL16842970 | 0.75 | ALDH1A1 (0.39) | ALDH1A1TDP1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL11069266 | 0.75 | MAPT (0.42) | ALDH1A1L3MBTL1CYP1A2CYP2D6MAPT | |
| SCHEMBL11074612 | 0.73 | CHKA (0.40) | ALDH1A1TDP1MAPTTSHRCHRNB4 | |
| Benzene SCHEMBL28083527 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TDP1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL453160 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TDP1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL9490577 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TDP1L3MBTL1KDM4ECYP1A2 | |
| SCHEMBL30959 | 0.73 | ALDH1A1 (0.67) | ALDH1A1TDP1L3MBTL1KDM4ECYP1A2 | |
| Biphenyl SCHEMBL27801558 | 0.71 | ALDH1A1 (0.60) | ALDH1A1TDP1L3MBTL1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768307-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3100723-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-2785178-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| EP-2720539-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| CN-103917093-B | Opsin binding ligands, compositions, and methods of use | 比卡姆药品公司 | 2017-08-11 | — | — | CN | disclosed |
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| CN-106431988-A | Opsin-binding ligands, compositions and methods of use | 比卡姆药品公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170037024-A1 | Opsin-Binding Ligands, Compositions and Methods for Use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-6649629-B2 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | NITROMED, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NICOX S.A. (FR) | 2003-10-30 | — | — | US | disclosed |
| WO-2003086282-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20020183366-A1 | Cyclooxygenase-2 inhibitors, compositions and methods of use | NICOX S.A. (FR) | 2002-12-05 | — | — | US | disclosed |
| WO-2002087508-A2 | NITROSATED AND NITROSYLATED NEBIVOLOL AND ITS METABOLITES, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-1246621-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| US-20020119977-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications | NICOX S.A. (FR) | 2002-08-29 | — | — | US | disclosed |
| WO-2002060378-A2 | SUBSTITUTED ARYL COMPOUNDS AS CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | NICOX S.A. (FR) | 2001-11-15 | — | — | US | disclosed |
| WO-2001045703-A1 | NITROSATED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137398-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | CRYAB, CRYAA, PDE6C | ALDH1A1 2166/4885TDP1 2584/4885L3MBTL1 1933/4885 |
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, UACA | ALDH1A1 2958/4885TDP1 2463/4885L3MBTL1 1042/4885 |
| US-20020119977-A1 | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications | PTGS2, PTGES2, PTGES | ALDH1A1 643/4885TDP1 2607/4885L3MBTL1 2618/4885 |
| US-20170037024-A1 | Opsin-Binding Ligands, Compositions and Methods for Use | CRYAB, CRYAA, PDE6C | ALDH1A1 2191/4885TDP1 2573/4885L3MBTL1 1898/4885 |
| US-20190023649-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, PDE6C | ALDH1A1 2346/4885TDP1 2588/4885L3MBTL1 1882/4885 |
| US-20020183366-A1 | Cyclooxygenase-2 inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | ALDH1A1 504/4885TDP1 1361/4885L3MBTL1 4121/4885 |
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NOS1, NOS2, NOS3 | ALDH1A1 507/4885TDP1 580/4885L3MBTL1 4258/4885 |
| US-20010041726-A1 | 4-(5-(4-chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl) -benzenesulfonamide, for example; treating gastrointestinal disorders, ulcer healing agents, treating disorders resulting from elevated cyclooxygenase (COX-2) | PTGS1, PTGS2, PTGES | ALDH1A1 334/4885TDP1 2457/4885L3MBTL1 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.